IL-34依赖的肾脏内与全身机制促进MRL-Faslpr小鼠狼疮性肾炎
在MRL-Faslpr狼疮小鼠模型中,IL-34通过促进骨髓单核细胞增殖及肾脏内巨噬细胞增殖导致巨噬细胞积聚,进而介导肾小管上皮细胞凋亡,并抑制自身抗体产生;敲除IL-34可减轻肾炎和全身病变。狼疮性肾炎患者肾脏IL-34、cFMS和PTPRZ表达与小鼠模型相似,且肾小管上皮细胞IL-34表达与疾病活动度相关。
要点
- IL-34通过骨髓和肾脏内巨噬细胞增殖促进狼疮性肾炎。
- 敲除IL-34可抑制肾炎、自身抗体和肾小球免疫复合物沉积。
- 肾小管上皮细胞IL-34表达与狼疮性肾炎疾病活动度相关。
核心结论
- IL-34是狼疮性肾炎有前景的新型治疗靶点。
研究设计与样本
- 比较表达IL-34的MRL-Faslpr小鼠与IL-34敲除的MRL-Faslpr小鼠的狼疮性肾炎和全身病变。
- 评估狼疮性肾炎患者中IL-34及cFMS、PTPRZ受体的表达。
主要发现
- 在MRL-Faslpr小鼠狼疮性肾炎中,肾脏内IL-34及其两个受体表达增加。
- 敲除IL-34的小鼠肾炎和全身病变受到抑制。
- IL-34通过促进骨髓单核细胞增殖(增加循环单核细胞,经趋化因子招募至肾脏)和肾脏内巨噬细胞增殖,导致巨噬细胞积聚,进而介导肾小管上皮细胞凋亡。
- 敲除IL-34的小鼠循环自身抗体和肾小球抗体沉积减少,肾脏和脾脏活化增殖B细胞减少。
- PTPRZ表达于巨噬细胞、B细胞和T细胞。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In people with SLE and in the MRL-Faslpr lupus mouse model, macrophages and autoantibodies are central to lupus nephritis. IL-34 mediates macrophage survival and proliferation, is expressed by tubular epithelial cells (TECs), and binds to the cFMS receptor on macrophages and to a newly identified second receptor, PTPRZ. METHODS: To investigate whether IL-34-dependent intrarenal and systemic mechanisms promote lupus nephritis, we compared lupus nephritis and systemic illness in MRL-Faslpr mice expressing IL-34 and IL-34 knockout (KO) MRL-Faslpr mice. We also assessed expression of IL-34 and the cFMS and PTPRZ receptors in patients with lupus nephritis. RESULTS: Intrarenal IL-34 and its two receptors increase during lupus nephritis in MRL-Faslpr mice. In knockout mice lacking IL-34, nephritis and systemic illness are suppressed. IL-34 fosters intrarenal macrophage accumulation via monocyte proliferation in bone marrow (which increases circulating monocytes that are recruited by chemokines into the kidney) and via intrarenal macrophage proliferation. This accumulation leads to macrophage-mediated TEC apoptosis. We also found suppression of circulating autoantibodies and glomerular antibody deposits in the knockout mice. This is consistent with fewer activated and proliferating intrarenal and splenic B cells in mice lacking IL-34, and with our novel discovery that PTPRZ is expressed by macrophages, B and T cells. These findings appear translatable to human patients with lupus nephritis, whose expression of IL-34, cFMS, and PTPRZ is similar to that seen in the MRL-Faslpr lupus mouse model. Moreover, expression of IL-34 in TECs correlates with disease activity. CONCLUSIONS: IL-34 is a promising novel therapeutic target for patients with lupus nephritis.
引用
- Wada Y, Gonzalez-Sanchez HM, Weinmann-Menke J, et al. IL-34-Dependent Intrarenal and Systemic Mechanisms Promote Lupus Nephritis in MRL-Faslpr Mice. J Am Soc Nephrol. 2019. PMID: 30622154. doi:10.1681/ASN.2018090901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。